358 filings
Page 6 of 18
8-K
pe2 fj2im8
9 Dec 20
Other Events
9:03am
PRER14A
fi1fpncb2ecsii
8 Dec 20
Preliminary revised proxy
4:11pm
CORRESP
hi162313c sqckz7ix
8 Dec 20
Correspondence with SEC
12:00am
UPLOAD
k1jio
7 Dec 20
Letter from SEC
12:00am
8-K
lfz9fi1eo2c2vhe7
4 Dec 20
Departure of Directors or Certain Officers
4:34pm
S-8
o92cim0kuqhoqy epord
24 Nov 20
Registration of securities for employees
8:26am
8-K
1y2567
13 Nov 20
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
xkqsyza
10 Nov 20
Miragen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
4:18pm
D
sddz6
6 Nov 20
$91M in equity, sold $91M, 22 investors
4:23pm
8-K
6wzkra 3q8
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K
sl2yga 7l98r5tz5zvl
14 Oct 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
9houu
5 Oct 20
Regulation FD Disclosure
4:09pm
8-K/A
v0vx0
1 Oct 20
Departure of Directors or Certain Officers
4:17pm
8-K
s27ksbda5wunbwg
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
pu258 fgil
20 Aug 20
Miragen Announces Results of Meeting with Fda Regarding the Design of Pivotal Trial for Cobomarsen In Atll
4:07pm
8-K
4vcq5j68htjrnmhjy6
5 Aug 20
Miragen Reports Second Quarter 2020 Financial Results and Provides Business Updates
4:06pm
8-K
rjie1fzwi38opzdf7
24 Jul 20
Cobomarsen Receives Orphan Drug Designation from the U.S. Fda for the Treatment of T-cell Lymphoma
6:07am